Loperamide Hydrochloride interactions
Checked as Loperamide in this data source.
Full monograph for Loperamide HydrochlorideCheck it against another medicine
Medicines
595 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Abiraterone Acetate | Major | Metabolism | Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors)… | 12 sources — open the full entry |
| Amiodarone Hydrochloride | Major | Absorption | Coadministration with drugs that inhibit the P-glycoprotein (P-gp) efflux transporter may increase the concentrations of loperamide in plasma and central… | 18 sources — open the full entry |
| Clarithromycin | Major | Metabolism | Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors)… | 12 sources — open the full entry |
| Clopidogrel + Aspirin | Major | Metabolism · Unknown | Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors)…2 documented mechanisms | 12 sources — open the full entry |
| Clopidogrel Bisulphate | Major | Metabolism | Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors)… | 12 sources — open the full entry |
| Cyclosporine (Oral) | Major | Absorption | Coadministration with drugs that inhibit the P-glycoprotein (P-gp) efflux transporter may increase the concentrations of loperamide in plasma and central… | 18 sources — open the full entry |
| Diltiazem Hydrochloride | Major | Absorption | Coadministration with drugs that inhibit the P-glycoprotein (P-gp) efflux transporter may increase the concentrations of loperamide in plasma and central… | 18 sources — open the full entry |
| ErythromycinLotionOral | Major | Metabolism | Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors)… | 12 sources — open the full entry |
| Esomeprazole + Amoxicillin + Clarithromycin | Major | Metabolism · Unknown | Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors)…2 documented mechanisms | 12 sources — open the full entry |
| Flibanserin | Major | Absorption | Coadministration with drugs that inhibit the P-glycoprotein (P-gp) efflux transporter may increase the concentrations of loperamide in plasma and central… | 18 sources — open the full entry |
| Furosemide + Spironolactone | Major | Absorption · Unknown | Coadministration with drugs that inhibit the P-glycoprotein (P-gp) efflux transporter may increase the concentrations of loperamide in plasma and central…2 documented mechanisms | 18 sources — open the full entry |
| Gemfibrozil | Major | Metabolism | Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors)… | 12 sources — open the full entry |
| Itraconazole | Major | Metabolism | Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors)… | 12 sources — open the full entry |
| Ketoconazole | Major | Metabolism | Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors)… | 12 sources — open the full entry |
| Ketoconazole + Zinc Pyrithione + Aleovera | Major | Metabolism | Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors)… | 12 sources — open the full entry |
| Lansoprazole + Amoxicillin + Clarithromycin | Major | Metabolism · Unknown | Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors)…3 documented mechanisms | 12 sources — open the full entry |
| Lapatinib | Major | Absorption | Coadministration with drugs that inhibit the P-glycoprotein (P-gp) efflux transporter may increase the concentrations of loperamide in plasma and central… | 18 sources — open the full entry |
| Lopinavir + Ritonavir | Major | Metabolism · Synergy | Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors)…2 documented mechanisms | 14 sources — open the full entry |
| Nelfinavir | Major | Metabolism | Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors)… | 12 sources — open the full entry |
| Nirmatrelvir + Ritonavir | Major | Metabolism | Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors)… | 12 sources — open the full entry |
| Posaconazole | Major | Metabolism | Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors)… | 12 sources — open the full entry |
| Quinine Sulfate | Major | Absorption · Synergy | Coadministration with quinidine may increase the concentrations of loperamide in plasma and central nervous system (CNS). Opioid and other adverse effects may… | 13 sources — open the full entry |
| Rabeprazole + Amoxicillin + Clarithromycin | Major | Metabolism · Unknown | Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors)…3 documented mechanisms | 12 sources — open the full entry |
| Spironolactone | Major | Absorption | Coadministration with drugs that inhibit the P-glycoprotein (P-gp) efflux transporter may increase the concentrations of loperamide in plasma and central… | 18 sources — open the full entry |
| Tacrolimus MonohydrateOralTopical | Major | Absorption | Coadministration with drugs that inhibit the P-glycoprotein (P-gp) efflux transporter may increase the concentrations of loperamide in plasma and central… | 18 sources — open the full entry |
| Verapamil Hydrochloride | Major | Absorption | Coadministration with drugs that inhibit the P-glycoprotein (P-gp) efflux transporter may increase the concentrations of loperamide in plasma and central… | 18 sources — open the full entry |
| Vonoprazan + Amoxicillin + Clarithromycin | Major | Metabolism · Unknown | Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors)…2 documented mechanisms | 12 sources — open the full entry |
| Voriconazole | Major | Metabolism | Coadministration with drugs that enhance the gastrointestinal absorption or inhibit the metabolism of loperamide (e.g., potent CYP450 3A4 or 2C8 inhibitors)… | 12 sources — open the full entry |
| Alfuzosin Hydrochloride | Moderate | Synergy | The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse… | 7 sources — open the full entry |
| Amisulpride | Moderate | Synergy | The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse… | 7 sources — open the full entry |
| Amitriptyline Hydrochloride | Moderate | Synergy | Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide. | 9 sources — open the full entry |
| Amitriptyline Hydrochloride + Chlordiazepoxide | Moderate | Synergy | Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide. | 9 sources — open the full entry |
| Apalutamide | Moderate | Absorption · Metabolism | Coadministration with apalutamide may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4, 2C9, 2C19, breast… | 5 sources — open the full entry |
| Aripiprazole | Moderate | Synergy | Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide. | 9 sources — open the full entry |
| Arsenic Trioxide | Moderate | Synergy | The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse… | 7 sources — open the full entry |
| Artemether + Lumefantrine | Moderate | Synergy | The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse…2 documented mechanisms | 9 sources — open the full entry |
| Asciminib | Moderate | Others | Coadministration with asciminib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. In vitro… | 1 sources — open the full entry |
| Asenapine Maleate | Moderate | Synergy | The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse… | 7 sources — open the full entry |
| Atomoxetine Hydrochloride | Moderate | Synergy | The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse… | 7 sources — open the full entry |
| Atropine Sulfate (Injection) | Moderate | Synergy | Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide. | 9 sources — open the full entry |
| Azithromycin DihydratebaseOphthalmic | Moderate | Synergy | The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse… | 7 sources — open the full entry |
| Beclometasone + Formoterol + Glycopyrronium | Moderate | Synergy | Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide. | 9 sources — open the full entry |
| Bicalutamide | Moderate | Synergy | The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse… | 7 sources — open the full entry |
| Brexpiprazole | Moderate | Synergy | Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide. | 9 sources — open the full entry |
| Brigatinib | Moderate | Excretion | Coadministration with brigatinib may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of P-glycoprotein (P-gp)… | 4 sources — open the full entry |
| Budesonide + Glycopyrronium Bromide + Formoterol Fumarate | Moderate | Synergy · Unknown | Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.2 documented mechanisms | 9 sources — open the full entry |
| Cabozantinib | Moderate | Synergy | The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse… | 7 sources — open the full entry |
| Capmatinib Hydrochloride | Moderate | Absorption | Coadministration with capmatinib may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of P-glycoprotein (P-gp)… | 1 sources — open the full entry |
| Ceritinib | Moderate | Synergy | The use of higher than recommended dosages of loperamide (e.g., through abuse or misuse) has been associated with serious and potentially fatal cardiac adverse… | 7 sources — open the full entry |
| Cetirizine HydrochloridebaseOphthalmic | Moderate | Synergy | Concurrent use of cetirizine or levocetirizine with alcohol or other agents that exhibit central nervous system (CNS) depressant effects may result in additive… | 10 sources — open the full entry |
Food & lifestyle
alcohol
ModerateSynergy
Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
What to do: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
4 sources
- Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7
- Gilman AG, eds., Nies AS, Rall TW, Taylor P "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc. (1990):
- "Product Information. Fycompa (perampanel)." Eisai Inc (2012):
- "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc (2015):
Conditions
Conditions in which Loperamide Hydrochloride needs care, as documented in this source.
Dysentery
MajorThe use of drugs with antiperistaltic activity (primarily antidiarrheal and antimuscarinic agents, but also antispasmodic agents such as dicyclomine or oxybutynin at high dosages) is contraindicated in patients with diarrhea due to pseudomembranous enterocolitis or enterotoxin-producing bacteria. These drugs may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella and Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics. Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged. In general, because antiperistaltic agents decrease gastrointestinal motility, they may delay the excretion of infective gastroenteric organisms or toxins and should be used cautiously in patients with any infectious diarrhea, particularly if accompanied by high fever or pus or blood in the stool. Some cough and cold and other combination products may occasionally include antimuscarinic agents for their drying effects and may, therefore, require careful selection when necessary.
6 sources
- Brown JW "Toxic megacolon associated with loperamide therapy." JAMA 241 (1979): 501-2
- Walley T, Milson D "Loperamide related toxic megacolon in Clostridium difficile colitis." Postgrad Med J 66 (1990): 582
- "Product Information. Imodium (loperamide)." Janssen Pharmaceuticals (2001):
- Marshall WF Jr, Rosenthal P, Merritt RJ "Atropine therapy and paralytic ileus in an infant." J Pediatr Gastroenterol Nutr 9 (1989): 532-4
- "Lomotil for diarrhea in children." Med Lett Drugs Ther 17 (1975): 104
- "Product Information. Atropine Sulfate (atropine)." ESI Lederle Generics (2022):
Liver Failure
ModerateTherapy with antiperistaltic agents should be administered with extreme caution in patients with hepatorenal disease or abnormal liver enzymes. Antiperistaltic agents are metabolized by the liver (diphenoxylate to an active form) and primarily excreted in the feces. Hepatic coma can be precipitated.
3 sources
- "Product Information. Imodium (loperamide)." Janssen Pharmaceuticals (2001):
- "Product Information. Kaopectate (attapulgite)." Pharmacia and Upjohn (2001):
- "Product Information. Pepto-Bismol (bismuth subsalicylate)." Procter and Gamble Pharmaceuticals (2001):
Megacolon, Toxic
ModerateDecreased intestinal motility and prolonged transit time have resulted in toxic megacolon in patients with acute ulcerative colitis. Paralytic ileus has also occurred. Antiperistaltic agent GI motility and prolongs transit time and therapy should be administered cautiously in these patients.
4 sources
- "Product Information. Imodium (loperamide)." Janssen Pharmaceuticals (2001):
- "Product Information. Kaopectate (attapulgite)." Pharmacia and Upjohn (2001):
- "Product Information. Pepto-Bismol (bismuth subsalicylate)." Procter and Gamble Pharmaceuticals (2001):
- Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison's Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division (1998):
Water-Electrolyte Imbalance
ModerateDiarrhea can cause severe dehydration and electrolyte imbalance. Fluid accumulation within the GI track due to antiperistaltic-associated decrease in peristalsis can further aggravate dehydration and electrolyte imbalance. Antiperistaltic agents should be administered cautiously in patients with electrolyte imbalance and rehydration and electrolyte replacement should be initiated prior to initiation of therapy.
3 sources
- "Product Information. Imodium (loperamide)." Janssen Pharmaceuticals (2001):
- "Product Information. Kaopectate (attapulgite)." Pharmacia and Upjohn (2001):
- "Product Information. Pepto-Bismol (bismuth subsalicylate)." Procter and Gamble Pharmaceuticals (2001):